Impaired oxytocin signalling in the central amygdala in rats with chronic heart failure

• Verfasst von: Althammer, Ferdinand [VerfasserIn]
• Verfasst von: Roy, Ranjan K. [VerfasserIn]
• Verfasst von: Kirchner, Matthew K. [VerfasserIn]
• Verfasst von: Lira, Elba Campos [VerfasserIn]
• Verfasst von: Schimmer, Stephanie [VerfasserIn]
• Verfasst von: Charlet, Alexandre [VerfasserIn]
• Verfasst von: Grinevich, Valéry [VerfasserIn]
• Verfasst von: Stern, Javier E. [VerfasserIn]
• Titel: Impaired oxytocin signalling in the central amygdala in rats with chronic heart failure
• Verf.angabe: Ferdinand Althammer, Ranjan K. Roy, Matthew K. Kirchner, Elba Campos Lira, Stephanie Schimmer, Alexandre Charlet, Valery Grinevich and Javier E. Stern
• E-Jahr: 2024
• Jahr: 15 November 2024
• Umfang: 22 S.
• Illustrationen: Illustrationen
• Fussnoten: Online verfügbar: 12. November 2024 ; Gesehen am 30.04.2025
• Titel Quelle: Enthalten in: The journal of physiology
• Ort Quelle: Hoboken, NJ : Wiley-Blackwell, 1878
• Jahr Quelle: 2024
• Band/Heft Quelle: 602(2024), 22, Seite 6259-6280
• ISSN Quelle: 1469-7793
• DOI: doi:10.1113/JP286297
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: amygdala
• Sach-SW: astrocyte
• Sach-SW: depression
• Sach-SW: electrophysiology
• Sach-SW: GABA
• Sach-SW: heart failure
• Sach-SW: mood
• Sach-SW: oxytocin
• K10plus-PPN: 1924037637

Abstract

Heart failure (HF) patients suffer from cognitive decline and mood impairments, but the molecular signals and brain circuits underlying these effects remain elusive. The hypothalamic neuropeptide oxytocin (OT) is critically involved in regulating mood, and OTergic signalling in the central amygdala (CeA) is a key mechanism that controls emotional responses including anxiety-like behaviours. Still, whether an altered OTergic signalling contributes to mood disorders in HF remains unknown. To address this, we used an ischaemic rat HF model, along with a highly multidisciplinary approach, to mechanistically study multiple levels of the hypothalamus-to-CeA OTergic circuit in male rats with HF. We aimed to test the hypothesis that sustained activation of the OT system following an infarct leads to depletion of OT content in this pathway, with subsequent changes in OT receptor expression and blunted modulation of local GABAergic circuits. We found that most of OTergic innervation of the CeA originated from the supraoptic nucleus (SON). While no differences in the numbers of SON→CeA OTergic neurons was observed between sham and HF rats, we observed a blunted content and release of OT from axonal terminals within the CeA. Moreover, we report downregulation of neuronal and astrocytic OT receptors, and impaired OTR-driven GABAergic synaptic activity within the CeA microcircuit of HF rats. We provide the first evidence that male HF rats display perturbations in the hypothalamus-to-amygdala OTergic circuit, laying the foundation for future translational studies targeting either the OT system or GABAergic amygdalar microcircuit to ameliorate mood impairments in rats or patients with chronic HF. Key points Heart failure patients suffer from cognitive decline, depression and mood impairments, but the underlying mechanisms remain elusive. Acting within the central amygdala, the neuropeptide oxytocin regulates emotional responses, including anxiety-like behaviours. However, whether changes in oxytocin signalling occurs during heart failure is unknown. In this study, we used an ischaemic rat heart failure model to mechanistically study multiple levels of the hypothalamus-to-amygdala oxytocinergic circuit in this disease. We report an overall blunted oxytocinergic signalling pathway in rats with heart failure, including blunted content and release of oxytocin from axonal terminals, downregulation of neuronal and astrocytic oxytocin receptors, and impaired oxytocin-driven GABAergic synaptic activity within the central amygdala microcircuit of HF rats. These studies shed light on mechanisms that contribute to mood disorders in cardiovascular disease states and help to identify potential molecular targets for their improved treatment.